Treatment of erythromelalgia with a serotonin/noradrenaline reuptake inhibitor
- 1 February 2002
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 146 (2) , 336-337
- https://doi.org/10.1046/j.1365-2133.2002.4653_6.x
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Platelet Inhibition by Sertraline and N-Desmethylsertraline: A Possible Missing Link Between Depression, Coronary Events, and Mortality Benefits of Selective Serotonin Reuptake InhibitorsPharmacological Research, 2001
- Mechanisms other than Shunting are Likely Contributing to the Pathophysiology of ErythromelalgiaJournal of Investigative Dermatology, 2000
- Erythromelalgia: New theories and new therapiesJournal of the American Academy of Dermatology, 2000
- Paroxetine decreases platelet serotonin storage and platelet function in human beingsClinical Pharmacology & Therapeutics, 2000
- Evidence of the Dual Mechanisms of Action of VenlafaxineArchives of General Psychiatry, 2000
- Microvascular Arteriovenous Shunting is a Probable Pathogenetic Mechanism in ErythromelalgiaJournal of Investigative Dermatology, 2000
- Impaired skin vasomotor reflexes in patients with erythromelalgiaClinical Science, 1999
- Erythromelalgia: Response to serotonin reuptake inhibitorsJournal of the American Academy of Dermatology, 1997
- Serotonin reuptake inhibitors in Raynaud's phenomenonThe Lancet, 1995
- Erythromelalgia as a form of neuropathyArchives of Dermatology, 1992